1
|
Prus AJ, Porter JH. The Discriminative Stimulus Properties of Drugs Used to Treat Depression and Anxiety. Curr Top Behav Neurosci 2019; 39:213-241. [PMID: 27352389 DOI: 10.1007/7854_2016_27] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Drug discrimination is a powerful tool for evaluating the stimulus effects of psychoactive drugs and for linking these effects to pharmacological mechanisms. This chapter reviews the primary findings from drug discrimination studies of antidepressant and anxiolytic drugs, including novel pharmacological mechanisms. The stimulus properties revealed from these animal studies largely correspond to the receptor affinities of antidepressant and anxiolytic drugs, indicating that subjective effects may correspond to either therapeutic or side effects of these medications. We discuss drug discrimination findings concerning adjunctive medications and novel pharmacologic strategies in antidepressant and anxiolytic research. Future directions for drug discrimination work include an urgent need to explore the subjective effects of medications in animal models, to better understand shifts in stimulus sensitivity during prolonged treatments, and to further characterize stimulus effects in female subjects. We conclude that drug discrimination is an informative preclinical procedure that reveals the interoceptive effects of pharmacological mechanisms as they relate to behaviors that are not captured in other preclinical models.
Collapse
Affiliation(s)
- Adam J Prus
- Department of Psychology, Northern Michigan University, Marquette, MI, USA.
| | - Joseph H Porter
- Department of Psychology, Virginia Commonwealth University, Richmond, VA, USA
| |
Collapse
|
2
|
McCreary AC, Filip M, Cunningham KA. Discriminative stimulus properties of (+/-)-fenfluramine: the role of 5-HT2 receptor subtypes. Behav Neurosci 2003; 117:212-21. [PMID: 12708517 DOI: 10.1037/0735-7044.117.2.212] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The role of serotonin 5-HT2 receptors (5-HT2R) in the discriminative stimulus effects of fenfluramine was investigated. Male Sprague-Dawley rats were trained to discriminate (+/-)-fenfluramine (2 mg/kg ip) from saline using a 2-lever, water-reinforced paradigm. Drug-lever responding after fenfluramine was dose-dependent. The 5-HT(2C/1B)R agonist mCPP and the 5-HT(2C)R agonist MK 212 fully substituted, whereas the 5-HT(2A/2C)R agonist DOI partially substituted, for the training drug. The 5-HT(2B)R agonist BW 723C86 engendered saline-lever responding. The 5-HT(2C/2B)R antagonist SB 206553 completely antagonized the fenfluramine discrimination a well as the full substitutions of mCPP and MK 212 and the partial substitution of DOI. The selective 5-HT(2A)R antagonist M100907 partially suppressed the stimulus effects of fenfluramine, mCPP, and MK 212 and almost fully attenuated the partial substitution of DOI. RS 102221, a selective 5-HT(2C)R antagonist that does not cross the blood-brain barrier, did not alter the fenfluramine cue. Results demonstrate that the discriminative stimulus effects of fenfluramine are centrally mediated by 5-HT(2C)R and to some extent by 5-HT(2A)R.
Collapse
Affiliation(s)
- Andrew C McCreary
- Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston 77555, USA
| | | | | |
Collapse
|
3
|
Smith RL, Gresch PJ, Barrett RJ, Sanders-Bush E. Stimulus generalization by fenfluramine in a quipazine-ketanserin drug discrimination is not dependent on indirect serotonin release. Pharmacol Biochem Behav 2002; 72:77-85. [PMID: 11900772 DOI: 10.1016/s0091-3057(01)00723-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The purpose of this study was to determine if animals trained to discriminate a serotonin2A (5-HT2A) receptor agonist from a 5-HT2A receptor antagonist would also be sensitive to alterations in serotonin neurotransmission brought about by 5-HT reuptake inhibitors and releasers. Previous work from our laboratory has shown that the quipazine-ketanserin discrimination is mediated solely by the 5-HT2A receptor, thus providing a behavioral continuum of 5-HT2A receptor function. Rats were trained to discriminate quipazine (0.35 mg/kg) from ketanserin (1.0 mg/kg) on a variable interval-30 schedule of reinforcement. Following acquisition, substitution tests were conducted with the training drug, quipazine, and agents that have been shown to alter the synaptic levels of 5-HT, including fenfluramine, norfenfluramine, 5-methoxy-6-methyl-2-aminoindan (MMAI) and fluoxetine. All compounds substituted, except fluoxetine. Antagonist tests with mianserin and MDL 100,907 indicated that fenfluramine's and MMAI's substitution for quipazine was mediated by the 5-HT2A receptor. Animals were pretreated with PCPA to determine whether 5-HT release or direct agonism mediated the discriminative stimulus effects of fenfluramine and MMAI. PCPA blocked the substitution of MMAI but not of fenfluramine for quipazine. Analysis of 3H-IP formation in cells showed that norfenfluramine dose-dependently stimulated phosphoinositide hydrolysis to levels similar to that of serotonin and quipazine. These results indicate that fenfluramine's substitution for quipazine in rats trained on a quipazine-ketanserin discrimination are due to direct agonism at the 5-HT2A receptor likely mediated by norfenfluramine, an active metabolite.
Collapse
Affiliation(s)
- Randy L Smith
- Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA
| | | | | | | |
Collapse
|
4
|
Sánchez H, Velázquez-Martínez DN. Discriminative stimulus properties of indorenate, a 5-HT1A, 5-HT1B and 5-HT2C agonist: a study in rats. J Psychopharmacol 2001; 15:29-36. [PMID: 11277605 DOI: 10.1177/026988110101500106] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Indorenate (INDO), initially described as an antihypertensive agent, also has some effects on behaviour, with anxiolytic and anorectic actions being reported. The aim of the present experiment was to examine the activity of INDO at the behavioural level at various serotonin (5-hydroxytryptamine, 5-HT) receptor sites by comparing its stimulus properties with those of other 5-HT receptor agonists and by examining its interactions with some 5-HT antagonists. Rats were trained to discriminate between 10.0 mg/kg INDO (administered intraperitoneally (90 min before the start of the session) from saline. A Fixed Ratio 10 (FR10) schedule of reinforcement was in effect in each drug condition. During generalization test sessions, the discrimination index (DI, responses to drug lever/responses to drug + saline lever) was calculated from the responses emitted before the first reinforcer of the session. DI was a function of the dose of INDO employed. Generalization to the discriminative stimulus properties of INDO was observed with the 5-HT1A receptor agonist 8-OH-DPAT (1.0 mg/kg produced 90% generalization) and the 5-HT(1B/2C) receptor agonist 1-(3-trifluoromethylphenyl) piperazine (TFMPP) (3.0 mg/kg produced up to 75% generalization). Yohimbine (5.6 mg/kg), buspirone (1.0 mg/kg), 6-chloro-2-(1-piperaziny)pyrazine (1.0 mg/kg) and m-chlorophenylpiperazine (mCPP) (1.0 mg/kg) induced a DI of 70%, 50% and 48% and 55%, respectively. In generalization tests, ritanserin (0.01-1.0 mg/kg) induced saline-like responding. NAN-190 (3.0 mg/kg), a 5-HT1A receptor antagonist, was able to reduce the DI of INDO to 50%. Although the 5-HT(2C/2A) receptor antagonists cinanserin (10.0 mg/kg) and metergoline (0.3 mg/kg) were able to reduce the stimulus properties of INDO to 60% and 30%, respectively, only ritanserin (1.0 mg/kg) reduced the stimulus properties of INDO to 25% with a clear dose-response relationship. The results suggest that INDO acts as an agonist at 5-HT1A receptor sites, but its activity at 5-HT(1B/2C) receptor sites also contributes to its discriminative function.
Collapse
MESH Headings
- 5-Methoxytryptamine/analogs & derivatives
- 5-Methoxytryptamine/pharmacology
- 8-Hydroxy-2-(di-n-propylamino)tetralin/pharmacology
- Animals
- Conditioning, Operant/drug effects
- Dose-Response Relationship, Drug
- Generalization, Psychological/drug effects
- Male
- Rats
- Rats, Wistar
- Receptor, Serotonin, 5-HT1B
- Receptor, Serotonin, 5-HT2C
- Receptors, Serotonin/drug effects
- Receptors, Serotonin, 5-HT1
- Serotonin Antagonists/pharmacology
- Serotonin Receptor Agonists/pharmacology
Collapse
Affiliation(s)
- H Sánchez
- Departamento de Psicofisiología, Facultad de Psicología, Universidad Nacional Autónoma de México, México DF
| | | |
Collapse
|
5
|
CHUN-FU WU, WEN LIU, JING LIU, CHYON-HWA YEH. dl-Fenfluramine inhibits ethanol-induced ascorbic acid release in rat striatum studied by microdialysis. Addict Biol 1998; 3:295-308. [PMID: 26734923 DOI: 10.1080/13556219872100] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
The effects of dl -fenfluramine, dl -5-hydroxytryptophan(5-HTP) and fluoxetine on ethanol-induced striatal ascorbic acid (AA) release in rat were studied by microdialysis coupled to high performance liquid chromatography with electrochemical detection. Ethanol (3.0 g/kg, i.p.) stimulated striatal AA release to more than 200% above the baseline. dl -Fenfluramine (20 mg/kg, i.p. or 40 mug/rat, i.c.v.), 10 min before ethanol administration, markedly inhibited ethanol-induced AA release. A similar result was also observed following dl -5-HTP (100 mg/kg, i.p.) administration. However, fluoxetine (10, 30 mg/kg, i.p.) showed no antagonistic effect on ethanol-induced AA release. The suppressing effect of dl -fenfluramine and dl -5-HTP on ethanolinduced AA release could be reversed by the 5-HT receptor antagonist cyproheptadine (10 mg/kg, s.c.). All these drugs had no effect on basal AA release. The results give a first evidence for the involvement of central serotonergic system, and suggest that differential activities may exist between dl -fenfluramine, dl -5-HTP and fluoxetine in regulating ethanol-induced AA release in rat striatum.
Collapse
|
6
|
Fasciano J, Steele T, Castagnoli N, Katz J, Ricaurte G. The effect of N-methylation on fenfluramine's neurotoxic and pharmacologic actions. Brain Res 1997; 763:182-90. [PMID: 9296558 DOI: 10.1016/s0006-8993(97)00110-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
N-Methylation separates methamphetamine's neurotoxic and pharmacologic effects. In particular, N-methylation eliminates methamphetamine's neurotoxic activity while preserving its behavioral pharmacologic activity. The purpose of the present studies was to determine whether N-methylation could also be used to separate fenfluramine's neurotoxic and pharmacologic effects. Fenfluramine-induced serotonin neurotoxicity was assessed by measuring serotonin axonal markers 2 weeks after fenfluramine administration. Pharmacologic effects of fenfluramine were assessed by measuring fenfluramine-induced anorexia and fenfluramine discrimination. Both fenfluramine and its N-methylated analog, N-methylfenfluramine, produced dose-related effects in food intake, drug-discrimination and neurotoxicity studies. Although N-methylation reduced the neurotoxic potency of fenfluramine, it also reduced its pharmacologic activity. Neurotoxic potency was reduced 4- to 8-fold (depending on brain region), while pharmacologic potency was reduced 4- to 10-fold (depending on paradigm). Notably, N-methylation did not change the efficacy of fenfluramine as a serotonin neurotoxin, anorectic agent or discrimination stimulus. These results indicate that fenfluramine's behavioral and neurotoxic effects, unlike those of methamphetamine, are not dissociated by N-methylation. Further, the present results suggest that the effectiveness of side-chain nitrogen substitution in separating the behavioral and neurotoxic effects of amphetamine derivatives is strongly influenced by ring substitutions.
Collapse
Affiliation(s)
- J Fasciano
- Department of Neurology, Johns Hopkins Medical Institutions, Baltimore, MD 21224, USA
| | | | | | | | | |
Collapse
|
7
|
|
8
|
Zajaczkowski W, Moryl E, Papp M. Discriminative stimulus effects of the NMDA receptor antagonists MK-801 and CGP 37849 in rats. Pharmacol Biochem Behav 1996; 55:163-8. [PMID: 8870053 DOI: 10.1016/0091-3057(95)02290-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Rats were trained to discriminate MK-801 (0.05 mg/kg, IP), an uncompetitive, or CGP 37849 (3 mg/kg, IP), a competitive NMDA receptor antagonist from saline, using a two-lever, operant drug discrimination paradigm. In generalization tests the role of dopaminergic and serotonergic systems in the discriminative stimulus effects produced by both NMDA receptor antagonists was studied with amphetamine (0.5 mg/kg), cocaine (5.0 and 7.5 mg/kg), and fenfluramine (2.5 and 5.0 mg/kg). Additionally, memantine (5.0, 7.5 and 10.0 mg/kg), an uncompetitive NMDA receptor antagonist, was tested. The discriminative stimuli produced by MK-801 and CGP 37849 were not generalized to each other. Among the tested drugs only memantine generalized to the MK-801 discriminative stimulus. None of the tested drugs showed CGP 37849-like discriminative stimulus properties. The different mechanisms underlying NMDA antagonism by MK-801 and GP 37849 might explain the observed lack of cross-generalization. The results suggest that dopaminergic and serotonergic systems are not of major importance in the discriminative stimulus effects produced by both MK-801 and CGP 37849.
Collapse
Affiliation(s)
- W Zajaczkowski
- Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
| | | | | |
Collapse
|
9
|
Locke KW, Levesque TR, Nicholson KL, Balster RL. Dexfenfluramine lacks amphetamine-like abuse potential. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20:1019-35. [PMID: 8888108 DOI: 10.1016/0278-5846(96)00081-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
1. The amphetamine-like abuse potential of dexfenfluramine (dFEN) was evaluated using drug discrimination and self-administration procedures. 2. Male Fischer rats were trained to discriminate either dFEN (1.0 mg/kg) or d-amphetamine (dAMP; 1.0 mg/kg) from saline in a two-choice discrete-trial avoidance paradigm. 3. In dAMP-trained rats, dFEN (0.5-4.0 mg/kg) engendered almost exclusively saline-appropriate responding. In dFEN-trained rats, dAMP (1.0-4.0 mg/kg) engendered entirely saline-appropriate responding in 3 of 6 rats and intermediate levels of dFEN-appropriate responding in the remaining animals. 4. Potential reinforcing effects of dFEN were also evaluated in 3 male rhesus monkeys trained to self-administer cocaine (i.v.) during daily 60 min sessions under a fixed-ratio (FR)-10 schedule. 5. Various doses of dFEN (30-1000 micrograms/kg/infusion) and dAMP (10 micrograms/kg/infusion) were substituted for cocaine in 4 consecutive daily sessions. In all subjects, dFEN maintained rates of self-administration within the range of rates maintained by saline and considerably below those maintained by cocaine and dAMP. Furthermore, the within-session distribution of responding with dFEN resembled that produced by saline. 6. Taken together, these results strongly suggest that dFEN will not have amphetamine-like abuse potential in humans.
Collapse
Affiliation(s)
- K W Locke
- Interneuron Pharmaceuticals Inc., Lexington, MA, USA
| | | | | | | |
Collapse
|
10
|
Marona-Lewicka D, Rhee GS, Sprague JE, Nichols DE. Psychostimulant-like effects of p-fluoroamphetamine in the rat. Eur J Pharmacol 1995; 287:105-13. [PMID: 8749023 DOI: 10.1016/0014-2999(95)00478-5] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The present study was undertaken to compare the pharmacological properties of p-fluoroamphetamine with those of amphetamine and of other halogenated amphetamines, using several in vivo and in vitro tests. These included substitution testing in (+)-amphetamine (1 mg/kg, 5.4 mu mol/kg, i.p.)-, (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine [(+)-MBDB] (1.75 mg/kg, 7.8 mu mol/kg, i.p.)-, and 5-methoxy-6-methyl-2-aminoindan (MMAI) (1.71 mg/kg, 8 mu mol/kg, i.p.)-trained rats, [3H]5-HT and [3H]dopamine uptake inhibition in whole brain synaptosomes, and changes in striatal extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) as measured by in vivo microdialysis in freely moving rats. In drug discrimination substitution tests, p-fluoroamphetamine fully mimicked (+)-amphetamine (ED50 0.43 mg/kg, 2.11 mu mol/kg), whereas 'no substitution' was observed in rats trained to discriminate the serotonin (5-hydroxytryptamine, 5-HT)-releasing agents (+)-MBDB or MMAI from saline. p-Chloroamphetamine did not substitute for amphetamine but fully substituted for the (+)-MBDB and MMAI cues (ED50 0.17 mg/kg, 0.82 mu mol/kg, and 0.14 mg/kg, 0.69 mu mol/kg, respectively). p-Fluoroamphetamine, in comparison with p-chloroamphetamine and p-iodoamphetamine, showed much stronger inhibition of [3H]dopamine than [3H]5-HT uptake into rat brain synaptosomes but was less selective than amphetamine. p-Fluoroamphetamine (7.0 mg/kg, i.p.), 1 h after administration, strongly elevated (849% of baseline) extracellular dopamine in rat striatum measured using in vivo microdialysis. Amphetamine (2 mg/kg, i.p.) increased extracellular dopamine in rat striatum with a maximum at the same time as did p-fluoroamphetamine, but the latter gave a smaller increase. The data presented suggest that p-fluoroamphetamine resembles amphetamie more than it does the 5-HT-releasing type amphetamines.
Collapse
Affiliation(s)
- D Marona-Lewicka
- Departments of Pharmacology and Toxicology, and Medicinal Chemistry and Pharmacognosy, Purdue University, West Lafayette, IN 47907, USA
| | | | | | | |
Collapse
|
11
|
Callahan PM, Cunningham KA. Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP). Eur J Pharmacol 1994; 257:27-38. [PMID: 8082704 DOI: 10.1016/0014-2999(94)90690-4] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Rats were trained to discriminate the 5-HT receptor agonist m-chlorophenylpiperazine (mCPP; 1 mg/kg) from saline using a two-lever, water-reinforced drug discrimination task. The antidepressant trazodone (1-8 mg/kg), the 5-HT1B/2C receptor agonists 1-(m-trifluoromethylphenyl)piperazine (TFMPP; 0.25-1 mg/kg) and MK 212 (0.125-1 mg/kg), and the mixed 5-HT1A/B receptor agonist RU 24969 (0.25-2 mg/kg) substituted fully for mCPP. The 5-HT2A/2C receptor agonists 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI; 0.25-1 mg/kg) and d-lysergic acid diethylamide (LSD; 0.02-0.08 mg/kg) and the 5-HT releaser fenfluramine (0.5-2 mg/kg) also mimicked mCPP. Agonists selective for the 5-HT1A or 5-HT3 receptor or the 5-HT reuptake site produced saline-lever responding. The ergoline derivative mesulergine (0.5-4 mg/kg) produced a partial agonist/antagonist profile. The 5-HT1/2 receptor antagonist metergoline (0.125-1 mg/kg) completely blocked the mCPP cue whereas the 5-HT2A/2C receptor antagonists ketanserin and LY 53857 as well as all other 5-HT receptor antagonists failed to block the mCPP cue. The dopamine receptor antagonists SCH 23390 and haloperidol were also ineffective mCPP antagonists. Following pretreatment with the 5-HT synthesis inhibitor p-chlorophenylalanine (pCPA; 100 mg/kg/day) for 3 consecutive days, the discriminability of low doses of mCPP increased, whereas the effects of fenfluramine decreased. The present results suggest that the discriminative stimulus effects of mCPP in rats are mediated primarily by postsynaptic 5-HT2C receptors.
Collapse
Affiliation(s)
- P M Callahan
- University of Texas Medical Branch, Department of Pharmacology and Toxicology, Galveston 77555-1031
| | | |
Collapse
|
12
|
Boja JW, Schechter MD. Possible serotonergic and dopaminergic mediation of the N-ethyl-3,4-methylenedioxyamphetamine discriminative stimulus. Eur J Pharmacol 1991; 202:347-53. [PMID: 1684158 DOI: 10.1016/0014-2999(91)90277-w] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Eight male rats previously trained to discriminate 2.0 mg/kg N-ethyl-3,4-methylenedioxyamphetamine (MDE) from its vehicle in a two-lever, food motivated task were utilized to characterize the stimulus properties of MDE. The 5-HT receptor agonists 1-(m-trifluoromethylphenyl)piperazine (TFMPP), quipazine and 6-methoxy-1,2,3,4 tetrahydro-beta-carboline were able to generalize to the stimulus produced by MDE. However, the 5-HT receptor agonists m-chlorophenylpiperazine (mCPP), buspirone and norfenfluramine, the dopamine receptor agonist amphetamine, as well as the acetylcholine receptor agonist arecoline did not completely generalize. In addition, the simultaneous administration of norfenfluramine and amphetamine generalized to MDE. Pretreatment with the serotonin receptor antagonists cinanserin and metergoline or the dopamine receptor antagonist haloperidol failed to completely inhibit the discriminative stimulus produced by MDE. Multiple p-chlorophenylalanine (PCPA) pretreatments significantly reduced MDE discrimination, whereas vehicle discrimination was unaffected. Five days following cessation of PCPA pretreatment, MDE discrimination returned to criterion levels and remained at that level. These results suggest that the stimulus produced by MDE involve a complex interaction of various neurotransmitters, with both serotonergic and dopaminergic components.
Collapse
Affiliation(s)
- J W Boja
- Department of Pharmacology, Northeastern Ohio Universities College of Medicine, Rootstown 44272
| | | |
Collapse
|
13
|
Schechter MD. Effect of serotonin depletion by p-chlorophenylalanine upon discriminative behaviours. GENERAL PHARMACOLOGY 1991; 22:889-93. [PMID: 1684770 DOI: 10.1016/0306-3623(91)90226-v] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
1. Para-chlorophenylalanine (p-CPA), a competitive inhibitor of the serotonin (5-HT) synthesis enzyme tryptophan hydroxylase, was administered to rats at a dosage (100 mg/kg daily for 3 days) that depletes 5-HT. 2. Different groups of these rats were previously trained to discriminate the interoceptive stimuli produced by amphetamine, cathinone, 3,4-methylenedioxymethamphetamine (MDMA), N-ethyl-3,4-methylenedioxyamphetamine (MDE), fenfluramine or yohimbine, and the effect of p-CPA pretreatment upon their discriminative performance was compared with the effect of saline (control) pretreatment. 3. p-CPA was shown to have no effect upon the dopaminergically-mediated stimuli produced by the stimulants amphetamine and cathinone or upon yohimbine performance. 4. p-CPA significantly decreased discriminative performance with the serotonergic releasing drugs MDMA, MDE and fenfluramine. This decrease in discriminative performance returned to pre-p-CPA (criterion) levels at a time (9-12 days) when 5-HT has been reported to replete to normal brain concentrations. 5. It is concluded that p-CPA pretreatment lowers brain 5-HT and, in turn, significantly decreases the ability of rats to discriminate centrally active drugs whose interoceptive cueing stimuli are mediated by 5-HT neurons.
Collapse
Affiliation(s)
- M D Schechter
- Department of Pharmacology, Northeastern Ohio Universities College of Medicine, Rootstown 44272
| |
Collapse
|
14
|
Abstract
Male Sprague-Dawley rats were trained to discriminate the anorectic drug d,l-fenfluramine (2.0 mg/kg intraperitoneally administered) from its vehicle using a food-motivated (fixed-ratio 10 schedule) two-lever operant task. Once trained, doses of 0.5, 1.0 and 1.5 mg/kg fenfluramine tested 20 min after IP administration produced dose-responsive discrimination performance. Subsequently, noncontingent twice-a-day administrations of 1 ml/kg saline were made for 4 days and the dose-effect relationship redetermined on the 13th to 15th day after initiation of the chronic saline regimen. Results of these dose-response experiments indicated that there was no significant effect upon fenfluramine discrimination after multiple saline injections or after 10 days without training. Following four days of retraining, 6.25 mg/kg fenfluramine twice-a-day for four days was followed 10 days later by another dose-response determination. This purportedly neurotoxic regimen of fenfluramine significantly increased the rats' ability to discriminate fenfluramine. These results suggest the possibility that chronic release of serotonin or selective damage to serotonin-containing neurons produced by fenfluramine may lead to postsynaptic supersensitivity as manifested by the functionally increased discriminative performance observed.
Collapse
Affiliation(s)
- M D Schechter
- Department of Pharmacology, Northeastern Ohio Universities College of Medicine, Rootstown 44272
| |
Collapse
|
15
|
NICHOLS DAVIDE, OBERLENDER ROBERT. Structure-Activity Relationships of MDMA and Related Compounds: A New Class of Psychoactive Drugs? Ann N Y Acad Sci 1990. [DOI: 10.1111/j.1749-6632.1990.tb16914.x] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
16
|
Abstract
Systemically administered serotonin, which does not pass the blood-brain barrier, inhibited nipple attachment behavior in 20- and 30-day-old rat pups. Xylamidine, a peripheral serotonin antagonist, attenuated the effects of serotonin, quipazine, and fenfluramine on nipple attachment behavior. Thus, serotonin receptors in the periphery may play an important role in the serotonergic inhibitory mechanism that has been hypothesized as the developing system leading to weaning. However, unlike more general 5-HT antagonists, xylamidine given alone failed to facilitate suckling, suggesting different sites of action for facilitation and inhibition of this infantile behavior.
Collapse
Affiliation(s)
- S T Bateman
- Department of Psychology, Dartmouth College, Hanover, NH 03755
| | | | | |
Collapse
|
17
|
Abstract
Ten male rats were trained to discriminate the anorectic drug d,l-fenfluramine (2.0 mg/kg intraperitoneally administered) from its vehicle using a food-reinforced (fixed-ratio 10 schedule) two-lever operant task. Once learned, the fenfluramine stimulus was dose-dependent (ED50 = 0.8 mg/kg) and stereoselective with the d-isomer (ED50 = 0.6 mg/kg) approximate twice as potent as the l-isomer (ED50 = 1.2 mg/kg). Time-course data indicate that the fenfluramine metabolite norfenfluramine produces a significantly faster onset and longer duration of action than does the parent compound. The results suggest that both stereoisomers of fenfluramine have discriminative stimulus properties and that the fenfluramine metabolite, norfenfluramine, contributes to the discriminative stimulus properties of the parent drug.
Collapse
Affiliation(s)
- M D Schechter
- Department of Pharmacology, Northeastern Ohio Universities, College of Medicine, Rootstown 44272
| |
Collapse
|
18
|
Schechter MD. Comparison of anorectic drugs in rats trained to discriminate between satiation and deprivation. Life Sci 1990; 47:17-24. [PMID: 2388514 DOI: 10.1016/0024-3205(90)90561-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Eight male rats were trained to discriminate between the internal states produced by food deprivation of 3 hours (satiation) and that produced by food deprivation of 27 hours duration (deprivation). One lever, in a two-lever operant chamber, had to be pressed to receive reinforcement in the satiation state, whereas pressing the other lever was required when the rat was in the deprivation state. Once the rats were trained, increasing the number of hours of food deprivation, from 1 to 48 hours, resulted in more deprivation-appropriate lever responses in the two-lever operant task. Administration of doses of fenfluramine (0.5-1.5 mg.kg), its active metabolite norfenfluramine (0.25-1.0 mg/kg) or d-amphetamine (0.5-1.5 mg/kg) produced a dose-responsive decrease in deprivation-appropriate responses when each drug/dose was injected (i.p.) 15 min prior to deprivation (27 hours) testing. Norfenfluramine was 1.5 times more potent than fenfluramine which was 1.5 times more potent than amphetamine.
Collapse
Affiliation(s)
- M D Schechter
- Department of Pharmacology, Northeastern Ohio Universities College of Medicine, Rootstown 44272
| |
Collapse
|
19
|
Fuller RW. Drugs affecting serotonin neurons. PROGRESS IN DRUG RESEARCH. FORTSCHRITTE DER ARZNEIMITTELFORSCHUNG. PROGRES DES RECHERCHES PHARMACEUTIQUES 1990; 35:85-108. [PMID: 2149771 DOI: 10.1007/978-3-0348-7133-4_3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Advances in serotonin pharmacology, the development of drugs that intervene at specific sites to modify serotonergic function, have accompanied advances in the understanding of physiologic roles of serotonin present in neurons and elsewhere and of serotonin receptors that are widely distributed in brain and many peripheral tissues. The pharmacologic advances have sometimes been stimulated by developments in serotonin physiology, such as the recognition of multiple serotonin receptor subtypes, and in other cases have been a major factor in providing new insights into physiologic roles of serotonin. Drugs that modify serotonin function have a variety of therapeutic applications currently and many more potential therapeutic uses to be explored in the future. Having drugs that act with high specificity or selectivity on particular enzymes in serotonin biosynthesis, on particular serotonin receptors, or at other sites such as uptake carriers for serotonin not only offers the hope of improved clinical therapy in diseases caused by abnormal serotonergic function or in which alteration of serotonergic function can alleviate symptoms, but also provides valuable pharmacologic tools for learning more about serotonin physiology and probing the functional status of serotonergic systems. The next few years promise to yield important new serotonergic drugs.
Collapse
Affiliation(s)
- R W Fuller
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285
| |
Collapse
|
20
|
|
21
|
Boja JW, Schechter MD. Norfenfluramine, the fenfluramine metabolite, provides stimulus control: evidence for serotonergic mediation. Pharmacol Biochem Behav 1988; 31:305-11. [PMID: 3244707 DOI: 10.1016/0091-3057(88)90350-4] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Nine male rats were trained to discriminate 1.4 mg/kg norfenfluramine (NF) from its vehicle using a two-lever, food-motivated, operant discrimination task. Once trained, the rats showed a dose-dependent decrease in responding on the NF-correct lever following decreased doses of NF (ED50 = 0.71 mg/kg). Administration of 2.0 mg/kg fenfluramine (FEN) produced 100% responding on the NF-correct lever and decreasing doses of FEN, likewise, produced a dose-dependent decrease in responding on the NF-correct lever (ED50 = 1.30 mg/kg). Time-course data indicated that NF has a fast onset and a peak effect at 20-60 min after administration. Analysis of the time-course data provided a half-life of approximately 8 hr. In contrast, FEN did not show the rapid onset that was observed with NF. However, NF had a similar peak effect and half-life. These results indicate a pharmacological similarity between NF and FEN. However, the difference in onset of action suggests a possible difference between the parent drug and its metabolite. The serotonergic agonists mCPP, DOI, 5-MeODMT and LSD generalized to 1.4 mg/kg NF, whereas neither TFMPP nor 8-OHDPAT generalized to NF. The dopaminergic agonist AMPH also did not generalize to NF. The implications of these findings are discussed.
Collapse
Affiliation(s)
- J W Boja
- Department of Pharmacology, Northeastern Ohio Universities College of Medicine, Rootstown 44272
| | | |
Collapse
|
22
|
Fuller RW, Snoddy HD, Robertson DW. Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release. Pharmacol Biochem Behav 1988; 30:715-21. [PMID: 2463643 DOI: 10.1016/0091-3057(88)90089-5] [Citation(s) in RCA: 119] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
d-Fenfluramine is an anorectic drug believed to act by enhancement on serotonergic function in the brain. d-Fenfluramine (or the racemate) releases serotonin through a carrier-dependent mechanism, and serotonin release is the mechanism usually thought to produce its serotonergic effects. However, d-fenfluramine also inhibits serotonin uptake in vitro, and serotonin uptake inhibition is sometimes suggested to contribute to its mechanism of anorectic activity. Neurochemical experiments were done to examine serotonin release and serotonin uptake inhibition as mechanisms of action of d-fenfluramine in rats and to compare d-fenfluramine to fluoxetine, a serotonin uptake inhibitor. d-Fenfluramine decreased serotonin concentration in rat brain as early as 1 hr; at 1 hr 5-hydroxyindoleacetic acid (5HIAA) concentration was slightly increased, but at later times 5HIAA was also decreased. Fluoxetine, in contrast, did not change serotonin concentration in whole brain but decreased 5HIAA concentration at all time points. At all time intervals studied, the 5HIAA/serotonin ratio was increased by d-fenfluramine (and by Ro 4-1284, a nonspecific serotonin releaser) but was decreased by fluoxetine, a serotonin uptake inhibitor. No decrease in 5HIAA concentration or in the 5HIAA/serotonin ratio was apparent at any time or after any dose of d-fenfluramine studied. The possibility that doses of d-fenfluramine below those needed for serotonin release might inhibit serotonin uptake was tested by determining whether d-fenfluramine could block the acute depletion of brain serotonin by p-chloroamphetamine, or the long-term neurotoxic effect of p-chloroamphetamine on brain serotonin neurons.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- R W Fuller
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285
| | | | | |
Collapse
|
23
|
Abstract
Various direct- and indirect-acting serotonin (5-HT) agonists serve as training drugs in tests of stimulus control of behavior; such agents include: 5-hydroxytryptophan, 5-methoxy-N,N-dimethyltryptamine, and fenfluramine. However, with the recent discovery of multiple populations of central 5-HT binding sites, the concept of site-selective serotonergic agents needs to be addressed. Certain 4-substituted 1-(2,5-dimethoxyphenyl)-2-aminopropanes such as DOM (4-methyl), DOB (4-bromo), and DOI (4-iodo) appear to be 5-HT2-selective agonists and serve as effective training drugs in rats. Stimulus generalization occurs among these agents regardless of which is used as the training drug, although stimulus generalization does not occur with 5-HT1A-selective agonists [e.g., 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH DPAT)] or with 5-HT1B-selective agonists [e.g., 1-(3-trifluoromethylphenyl)piperazine (TFMPP)]. 8-OH DPAT and TFMPP also serve as training drugs; the 8-OH DPAT-stimulus generalizes to other 5-HT1A agonists, but not to 5-HT1B or 5-HT2 agonists, whereas the TFMPP-stimulus generalizes to other 5-HT1B agonists, but not to 5-HT1A or 5-HT2 agonists. Classical serotonin antagonists, most of which are rather selective for 5-HT2 sites, and 5-HT2-selective antagonists are able to block the stimulus effects of DOM, DOB, and DOI, but not those of 8-OH DPAT or TFMPP. The results of such studies reveal that, in rats, site-selective 5-HT agonists produce stimulus effects that are also selective; although generalization may occur with nonselective 5-HT agonists, animals trained to discriminate site-selective 5-HT agonists apparently do not recognize other 5-HT agonists that are selective for a different site. Animals trained to discriminate such agents from saline might be useful for the identification and/or investigation of novel site-selective agonists and antagonists (for example, the 8-OH DPAT-stimulus generalizes to members of a new class of anxiolytics that display high affinity for 5-HT1A binding sites), and might also aid in the overall understanding of central serotonergic mechanisms.
Collapse
Affiliation(s)
- R A Glennon
- Department of Medicinal Chemistry, School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298
| |
Collapse
|
24
|
Abstract
To further clarify the role of 5-hydroxytryptamine (5HT) in the behavioral effects of tetrahydro-beta-carboline, male rats were trained to discriminate either 20 mg/kg THBC from its vehicle (n = 10) or 2.0 mg/kg fenfluramine from saline (n = 5). THBC was observed to produce fenfluramine-like effects in the fenfluramine-trained rats while fenfluramine produced THBC-like effects in the THBC-discriminating rats. To investigate which of the serotonergic receptors may mediate the THBC-induced discriminative stimulus, various putatively specific 5HT agonists were administered to THBC-trained rats. Results indicate that the 5HT1B receptor agonists TFMPP and m-CPP substitute for THBC in a dose-response manner whereas 5HT1A agonists do not generalize to the THBC-induced discriminative stimulus. These observations support a role for the 5HT1B receptor site in the discriminative stimulus properties of THBC.
Collapse
Affiliation(s)
- M D Schechter
- Department of Pharmacology, Northeastern Ohio Universities, College of Medicine, Rootstown 44272
| |
Collapse
|
25
|
Schechter MD. Fenfluramine discrimination in obese and lean Zucker rats: serotonergic mediation of effect. Eur J Pharmacol 1986; 125:135-41. [PMID: 3732388 DOI: 10.1016/0014-2999(86)90092-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Genetically obese Zucker rats and their lean littermates were trained to discriminate between the stimulus properties of 2.0 mg/kg fenfluramine and its vehicle in a two-lever, food-motivated operant task. Both groups learned the discrimination at the same rate and all rats showed a dose-related decrease in discriminative performance with lower fenfluramine doses. Analysis of the dose-response curves indicated an ED50 for the obese rats of 0.56 mg/kg and for the lean group of 0.42 mg/kg. Time-course experiments indicted that the obese rats maintain errorless discrimination through 90 min post-injection but discriminate significantly less than the lean rats at 960 min post-administration. These results suggest a similar sensitivity to fenfluramine in obese and lean rats with a difference in the time-course of drug action. Pre-treatment with the specific serotonin receptor antagonist pirenperone significantly attenuated fenfluramine discrimination in lean rats without a similar effect in the obese rats. Possible reasons for this observation are offered.
Collapse
|
26
|
Abstract
Groups of rats were trained to discriminate the stimulus properties of dopaminergically and/or serotonergically active drugs, viz., apomorphine, fenfluramine, tetrahydro-beta-carboline (THBC) and l-cathinone. Once trained, these animals were given several doses of drugs used in training and dose-response relationships and ED50 values were generated. Subsequently, each group of trained rats was administered various doses of 3,4-methylenedioxymethamphetamine (MDMA) to test generalization of the interoceptive cue of the drug used for training to MDMA. Rats trained to fenfluramine, THBC, and l-cathinone were observed to discriminate MDMA in a manner similar to the drug state to which they had been trained. Analysis of dose-response curves suggested that MDMA may be acting both as an indirect dopaminergic agonist and as a serotonergic receptor agonist. This duality of effect of MDMA has been evidenced by other studies and may account for its present abuse potential.
Collapse
|
27
|
Abstract
Rats were trained to discriminate between the stimulus properties of tetrahydro-beta-carboline (THBC) and its vehicle in a two-lever, food-motivated operant task. By steadily increasing the training dose, the discrimination was attained at 20.0 mg/kg THBC. Dose-response experiments subsequently indicated that decreasing doses of THBC produced decreased discrimination and generated an ED50 = 3.63 mg/kg. Administration of the serotonergically-active drug, fenfluramine, produced THBC-appropriate responding in a dose-responsive manner. In addition, LSD and yohimbine produced partial generalizations in the THBC-trained rats. These data suggest that the discriminative stimulus properties of THBC are mediated by serotonergic neurons in the central nervous system.
Collapse
|
28
|
Cunningham KA, Callahan PM, Appel JB. Discriminative stimulus properties of the serotonin agonist MK 212. Psychopharmacology (Berl) 1986; 90:193-7. [PMID: 3097699 DOI: 10.1007/bf00181240] [Citation(s) in RCA: 35] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
In an attempt to clarify the role of 5-hydroxytryptamine (5-HT) in the discriminative stimulus properties of MK 212 (6-chloro-2[1-piperazinyl]pyrazine), male Sprague-Dawley rats were trained to discriminate 0.5 mg/kg of this compound from saline. While the putative 5-HT agonists fenfluramine and m-chlorophenylpiperazine (MCPP) mimicked MK 212 in a dose-related manner, d-lysergic acid diethylamide (LSD), 8-hydroxy-2(di-n-propylamino)tetralin (8-OHDPAT), 5-methoxy-N,N-dimethyltryptamine (5-MeODMT), quipazine, Ru 24969, and 1-(m-trifluoromethylphenyl)piperazine (TFMPP) failed to substitute completely. The 5-HT1/5-HT2 antagonists BC 105, metergoline, and methysergide completely blocked the MK 212 cue, while the selective 5-HT2 antagonists ketanserin and pirenperone, the dopamine antagonists haloperidol and spiperone, and the beta-noradrenergic antagonist propranolol were without effect. The substitutions of fenfluramine and MCPP for MK 212 support a role for 5-HT in the MK 212 cue; however, the lack of substitution of many other 5-HT agonists is difficult to explain. The complete antagonism by 5-HT1/5-HT2 but not by selective 5-HT2, antagonists suggests the possibility that 5-HT1 receptors mediate the stimulus properties of MK 212. Further research is needed to support this hypothesis and to investigate the relative role of 5-HT and other neurotransmitters in the stimulus effects of MK 212.
Collapse
|
29
|
Abstract
Recent findings in this laboratory with regard to tolerance to fenfluramine anorexia are reviewed with respect to generality of the behavioural phenomenon. A systematic relationship between initial body weight and fenfluramine-induced weight change in rats is described. The possible roles of peripheral factors in fenfluramine anorexia and tolerances, including gastric emptying and peripheral serotonin, are discussed. The role of central factors is also considered. It appears that fenfluramine, and possibly other anorectic agents have multiple sites of action and affect multiple behaviours. Some clinical implications are noted.
Collapse
|
30
|
Young R, Glennon RA. Discriminative stimulus properties of amphetamine and structurally related phenalkylamines. Med Res Rev 1986; 6:99-130. [PMID: 3512936 DOI: 10.1002/med.2610060105] [Citation(s) in RCA: 73] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
31
|
|
32
|
Abstract
The possible peripheral anorectic actions of 5-hydroxytryptophan (5-HTP) and fenfluramine were examined in food-deprived rats. In a 1-h feeding test the peripherally acting 5-HT antagonist, xylamidine, attenuated the reductions in food intake induced by 5-HT and 5-HTP but not fenfluramine. Thus, the anorectic action of 5-HTP appears to be mediated in part by peripheral 5-HT receptors. Microstructural analyses showed that 5-HTP and fenfluramine induced decreases in eating rate and bout size. Xylamidine reversed the effect of 5-HTP on eating rate, and induced a slight increase in bout size in its own right. Therefore, the peripheral effect of 5-HTP appears to be a slowing of eating rate. No effects of xylamidine on fenfluramine induced changes in feeding were observed. The results indicate a dissociation of the anorectic effects of 5-HTP and fenfluramine based on a peripheral action of 5-HTP. The peripheral action of 5-HTP differs from the previously reported reductions in bout size and bout duration induced by 5-HT. Possible mechanisms for this difference in the peripheral actions of 5-HT and 5-HTP are discussed.
Collapse
|
33
|
Schechter MD, Finkelstein JA. Effect of dopamine agonists and fenfluramine on discriminative behavior in obese and lean Zucker rats. Pharmacol Biochem Behav 1985; 23:7-11. [PMID: 4034621 DOI: 10.1016/0091-3057(85)90121-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Dopamine agonists and fenfluramine were used as pharmacological probes to investigate the possible difference in sensitivity and time course of drug action in genetically obese Zucker rats and their lean littermates. All rats were trained to discriminate between the stimulus properties of 0.6 mg/kg d-amphetamine and its vehicle in a two-lever, food-motivated operant task. Once trained, both groups of rats showed a dose-related decrease in discriminative performance with lower amphetamine doses. Analysis of the dose-response curves indicated an ED50 for the obese rats of 0.17 mg/kg and for the lean group of 0.14 mg/kg. Administration of 0.3-1.2 mg/kg l-amphetamine and 2.5-10.0 mg/kg cocaine produced a pattern of responding similar to that observed with d-amphetamine. In contrast, 0.08-mg/kg apomorphine produced saline-appropriate responding and 1.5-2.5 mg/kg fenfluramine produced intermediate results in both groups. Time-course experiments indicated that the lean rats maintain errorless discriminative performance through 90 min post-injection, whereas the obese rats discriminate d-amphetamine significantly less at that post-administration time. The results suggest a similar sensitivity to d-amphetamine and other dopaminergic agonists in obese and lean rats with a difference in the time-course of d-amphetamine's action between these two groups.
Collapse
|